allogenic mesenchymal stem cells derived exosome enriched by mir-124
Cell therapyexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 17, 2018 (NCT03384433)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07192666 | Early Phase 1 (Phase 1) | Sep 15, 2025 | Guangdong ProCapZoom Biosciences Co., Ltd. |
| NCT06600529 | N/A | Aug 13, 2024 | Iffat Anwar Medical Complex |
| NCT06466850 | N/A | Jan 1, 2024 | Isfahan University |
| NCT05523011 | Phase 1 | Mar 8, 2022 | National University of Singapore, Paracrine, INC. |
| NCT03384433 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2018 | Isfahan University, Shahid Beheshti University of Medical Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Isfahan University | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Guangdong ProCapZoom Biosciences Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Iffat Anwar Medical Complex | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National University of Singapore | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Paracrine, INC. | For profit | 1 | 1 | 1 | 2022 |
| Shahid Beheshti University of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1